Esophageal Cancer, Osteoporosis, Sarcopenia
Conditions
Brief summary
Esophagectomy is most curative treatment to esophageal cancer. However, osteoporosis , which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after surgery. The aim of the present study was to evaluate osteoporosis by using high-resolution peripheral quantitative computed tomography (HR-pQCT) in the long course after esophagectomy. At least 3 years should have elapsed since operation without recurrence of esophageal cancer.
Detailed description
The patients after esophagectomy loss appetite and decrease the weight. Esophagectomy especially cause severe sarcopenia and metabolic change. Osteoporosis, which is characterized by both the loss of bone mass and the deterioration of bone architecture, is a serious complication in the long course after esophagectomy. The primary tools for assessing volumetric density and bone structure are quantitative computed tomography (QCT) and more recently, high-resolution peripheral quantitative computed tomography (HR-pQCT). However the validation of osteoporosis with HR-pQCT in the long course after esophagectomy remain elusive. The aim of the present study was to evaluate osteoporosis by using HR-pQCT in the long course after esophagectomy. At least 3 years should have elapsed since esophagectomy without any recurrence.
Interventions
PROCEDUREesophagectomy
esophagectomy
Sponsors
Nagasaki University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
50 Years to 90 Years
Healthy volunteers
Yes
Inclusion criteria
* At least 3 years have elapsed since esophagectomy due to esophageal cancer * Provide signed informed consent
Exclusion criteria
* Current use of the following osteoporosis agents; Teriparatide, Denosumab, and - - * bisphosphonate * Present malignancy (except in situ carcinoma) * Radiotherapy * Any condition that required chronic (greater than three months cumulative and greater than 5 mg/day) glucocorticoid therapy * Other diseases which affect bone metabolism Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures Received \> 3 months (or equivalent) of osteoporosis treatment Currently enrolled in or has not yet completed at least 1 month since ending other investigational device or drug trial(s), or subject is receiving other investigational agent(s).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparing bone microstructure in control and Esophagectomy groups | 1day | volumetric bone mineral density |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparing bone microstructure with serum biomarkers of osteoporosis | 1day | Correlation between bone mineral density in esophagectomy and biomarkers (25-hydroxyvitaminD, calcium, iPTH, P1NP, ICTP, TRACP5b) |
| Comparing bone microstructure with dual-energy X-ray absorptiometry | 1day | Correlation of bone mineral density between esophagectomy and DXA |
Contacts
Primary ContactShinichiro Kobayashi
Outcome results
None listed